4613347902

Tie2-expressing monocytes, blood “resident” monocytes, and embryonic macrophages suggests common fimctions and developmental relationships. Blood 114, 901-914.

Puhlmann, J., Puehler, F., Mumberg, D., Boukamp, P., and Beier, R. (2010). Racl is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Oncogene 29, 2205-2216.

Qiao, J., Kottke, T., Willmon, C., Galivo, F., Wongthida, P., Diaz, R.M., Thompson, J., Ryno, P., Barber, G.N., Chester, J., et al. (2008a). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T celi therapy, oncolytic virotherapy and immunotherapy. Nat. Med. 14, 37-44.

Qiao, J., Wang, H., Kottke, T., Diaz, R.M., Willmon, C., Hudacek, A., Thompson, J., Parato, K., Bell, J., Naik, J., et al. (2008b). Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. GeneTher. 15, 604-616.

Radoja, S., Rao, T.D., Hillman, D., and Frey, A.B. (2000). Mice bearing late-stage tumors have normal functional systemie T celi responses in vitro and in vivo. The Journal of Immunology 164, 2619-2628.

Raz, Y., and Erez, N. (2013). An inflammatory vicious cycle: Fibroblasts and immune celi reeruitment in cancer. Exp. Celi Res. 319,1596-1603.

Reeves, R.H., 0'Hara, B.F., Pavan, W.J., Gearhart, J.D., and Haller, O. (1988). Genetic mapping of the Mx influenza virus resistance gene within the region of mouse chromosome 16 that is homologous to human chromosome 21. J. Virol. 62,4372-4375.

Reichard, K.W., Lorence, R.M., Cascino, C.J., Peeples, M.E., Walter, R.J., Fernando, M B., Reyes, H.M., and Greager, J.A. (1992). Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 52,448-453.

Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Wein, L.M., Andrews, J., Randlev, B., Heise, C., Uprichard, M., Hatfield, M., et al. (2002). Hepatic Arterial Infusion of a Replication-selective Oncolytic Adenovirus (dl 1520): Phase II Viral, Immunologie, and Clinical Endpoints. Cancer Res. 62, 6070-6079.

Reits, E.A.J., Vos, J.C., Gromme, M., and Neefjes, J. (2000). The major substrates for TAP invivo are derived from newly synthesized proteins. Naturę 404, 774-778.